





**U.S. Food and Drug Administration**



**CENTER FOR FOOD SAFETY AND APPLIED NUTRITION**

[FDA Home Page](#) | [CFSAN Home](#) | [Search/Subject Index](#) | [Q & A](#) | [Help](#)

July 10, 2003

## **Consumer Health Information for Better Nutrition Initiative Task Force Final Report**

[Return to Table of Contents](#)

# **Attachment E - Interim Procedures for Qualified Health Claims Guidance: Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements**

### **BACKGROUND**

The Task Force recommends that FDA issue this document as final guidance setting out interim procedures that the agency intends to use for qualified health claims in the labeling of conventional human food and dietary supplements.

### **OBJECTIVE**

As part of this Initiative, the Task Force has recommended regulatory alternatives or options for FDA to consider (see Attachment A of this Task Force Report). The Task Force also recommended that FDA use the following interim procedures to ensure that its premarket review is consistent with the spirit of the Nutrition Labeling and Education Act and the First Amendment. FDA will continue to evaluate unqualified health claims under its current regulatory process and standard for significant scientific agreement (21 CFR 101.14 and 101.70).

#### **I. Criteria for Exercise of Enforcement Discretion**

FDA plans to establish criteria for considering exercising enforcement discretion for qualified health claims based on the extent to which the totality of the publicly available evidence supports the claim (see Attachment B). Different levels of evidence would result in

different qualifying language, as described in Table 2 , which provides standardized language for the B, C, and D categories to be used as part of the qualifying language for qualified health claims until consumer research (Attachment D) is completed.

**Table 1. Standardized Qualifying Language for Qualified Health Claims.**

Scientific Ranking <sup>1</sup>	FDA Category	Appropriate Qualifying Language <sup>2</sup>
Second Level	B	... "although there is scientific evidence supporting the claim, the evidence is not conclusive."
Third Level	C	"Some scientific evidence suggests ... however, FDA has determined that this evidence is limited and not conclusive."
Fourth Level	D	"Very limited and preliminary scientific research suggests... FDA concludes that there is little scientific evidence supporting this claim."
<p><sup>1</sup>From Final Guidance: Interim Evidence-based Ranking System for Scientific Data.</p> <p><sup>2</sup>The language reflects wording used in qualified health claims as to which the agency has previously exercised enforcement discretion for certain dietary supplements. During this interim period, the precise language as to which the agency considers exercising enforcement discretion may vary depending on the specific circumstances of each case.</p>		

**II. Procedures**

- A. *Filing Review* - FDA plans to begin accepting petitions for qualified health claims on September 1, 2003. Within 45 days of receipt of a qualified health claim petition, FDA intends to determine whether the petition is complete (see Section III below). If the petition is incomplete, the agency plans to inform the petitioner of the deficiencies and what steps the petitioner should take to rectify these deficiencies. If FDA determines that the petition is complete, it intends to file the petition. The agency recognizes that it can evaluate petitions more efficiently and effectively if they are well-organized and contain all the relevant information. FDA encourages potential petitioners to meet with the agency prior to preparing a petition to discuss their plans.
  
- B. *Prioritization* - FDA has only limited resources for reviewing health claims. Thus, to maximize the public health benefit of its claims review process. FDA intends to prioritize on a case-by-case basis all complete petitions according to several factors, including whether the food or dietary supplement that is the subject of the petition is likely to have a significant impact on a serious or life-threatening illness; the strength of the evidence; whether consumer research has been provided to show the claim is not misleading; whether the substance of the claim has undergone an FDA safety review (i.e., is an authorized food additive, has been GRAS affirmed, listed, or has received a letter of "no objection" to a GRAS notification); whether the substance that is the subject of the claim has been adequately characterized so that the relevance of available studies can be evaluated; whether the disease is defined and evaluated in

accordance with generally accepted criteria established by a recognized body of qualified experts; and whether there is prior review of the evidence or the claim by a recognized body of qualified experts.

- C. *Opportunity for Public Comment* - Upon filing of a petition, FDA intends to post the petition on its website and request public comment for 60 days. FDA plans to post comments submitted by the public on FDA's website or to make comments available for public review at the Division of Dockets Management, HFA-305.
- D. *Scientific Review* - After the comment period closes, FDA may pursue any one of several options for scientific review of data submitted in a petition in support of the substance/disease relationship. For example, FDA may conduct the review internally, it may convene an advisory subcommittee, or it may use appropriate third-party reviewers under contract to FDA, e.g., the Agency for Healthcare Quality and Research (AHRQ). In the case of a petition forwarded to AHRQ, AHRQ plans to send the petition to an Evidence-Based Practice Center (EPC) with which it has a contract to review the scientific evidence in the petition and to rank the degree of scientific certainty of the validity of the substance/disease relationship. AHRQ also plans to ask the EPC to review those science-related public comments received by FDA that discuss or provide evidence. Within 120 days after the commencement of the third party review, FDA would expect to receive a report that includes a description of the evidence reviewed, an analysis of that evidence, a summary of and response to public comments that pertain to the evidence, and its assessment as to the degree of scientific certainty in support of the substance/disease relationship.
- E. *Consolidation of Like Petitions* - If FDA receives more than one petition for a qualified health claim that describes the same relationship between a substance and a disease or health-related condition during its review, the agency plans to consolidate all of the related petitions received, if appropriate
- F. *Consultation with Other Federal Agencies* - To fully inform FDA's review, FDA intends, as appropriate, on a case-by-case basis, to consult with other scientific Federal agencies with official responsibility for public health protection or research related to human nutrition and dietary supplements.
- G. *Regulatory Decision* - As mentioned above, FDA plans to either conduct its own scientific review or use an appropriate third party to conduct a scientific review. In the case of third party review, after FDA receives, for example the EPC report, FDA intends, based on the totality of the publicly available evidence, public comment, and other relevant regulatory considerations, to determine whether to consider exercising enforcement discretion with respect to the proposed claim. If FDA decides to consider exercising enforcement discretion, the agency plans to determine what qualifying statement(s) and other information should accompany the claim to ensure that it is truthful and not misleading. In reaching its determination, FDA intends to review and evaluate the third party report, the totality of the publicly available evidence, and all of the public comments submitted within the comment period, as well as consider how the proposed qualified claim may affect consumers' dietary choices. FDA also intends to consider whether to exercise enforcement discretion with respect to other requirements in 21 CFR 101.14, and what other factors, in addition to qualifying

language, are relevant to considering the exercise of enforcement discretion.

- H. *Notification to Petitioner* - On or before day 270 after receipt of the filed petition, FDA plans to notify the petitioner in a letter of: a) the agency's determination; b) the basis for its determination; and c) if the agency decides to consider exercising enforcement discretion, the qualified claim for which the agency intends to consider exercising such discretion and the provisions of 21 CFR 101.14 for which the agency intends to consider exercising such discretion. FDA also plans to notify the petitioner of any other factors the agency intends to consider in deciding whether to exercise enforcement discretion when the claim appears in labeling of conventional human food or dietary supplements. FDA plans to post the letter and any third party report on the agency's website.
- I. *Extensions* - If the agency determines that it is appropriate, upon good cause, FDA may, decide to extend by 30-60 days the time period to notify the petitioner.
- J. *Reconsideration* - If a petitioner or other party disagrees with an FDA determination, that party may request reconsideration. FDA intends to reconsider its determination if the party presents significant new relevant evidence or provides a persuasive analysis that the agency's interpretation of the original evidence was incorrect. FDA intends to use the same process described above for reconsideration of the agency's determination. FDA may, on its own initiative, decide to reconsider a determination.

### III. Content of Petitions

- 1. *Requirements* - Except as described in III B (below), the agency believes that the requirements of 21 CFR 101.70 continue to apply, including the requirement to demonstrate that the substance that is the subject of the claim is safe and lawful under 21 CFR 101.14(b)(3)(ii).
- 2. *Summary of Scientific Information* - FDA intends to exercise enforcement discretion with respect to the requirement in 21 CFR 101.70 that the summary establish that the proposed claim is supported by significant scientific agreement. Instead, the summary should explain how credible evidence supports the claim as worded in the petition and why the petitioner believes that the specific wording of the claim, including any explanatory information, disclaimer or other qualification, is accurate and not misleading. As required by 21 CFR 101.70, the summary should include an analysis of the potential effect of the claim on total intakes of the substance (i.e., current intakes plus increases due to the claim), including any adverse or beneficial changes in dietary practices. The agency encourages petitioners to include relevant consumer research to document consumer understanding. FDA recommends that the consumer research address the research questions set out in Attachment D of the Task Force Report.

---

Task Force Final Report - Table of Contents

---

[CFSAN Home](#) | [CFSAN Search/Subject Index](#) | [CFSAN Disclaimers & Privacy Policy](#) | [CFSAN Accessibility/Help](#)  
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#)

FDA/Center for Food Safety & Applied Nutrition  
 Hypertext updated by [las/ear](#) August 23, 2004